Streetbeat News

Revenues

AR

Antero Resources (NYSE:AR) received mixed analyst ratings with 3 bullish, 1 somewhat bullish, and 2 indifferent. The average 12-month price target is $27.83, down 16.17% from the previous $33.20. Analysts from Raymond James, Benchmark, Mizuho, Wells Fargo, and Truist Securities have adjusted their ratings and price targets. Antero Resources is engaged in natural gas and liquids production, with a market cap below industry average, a -56.22% revenue decline as of September 30, 2023, low net margin, ROE, and ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 8:00 pm

DXC

DXC Technology (NYSE:DXC) has been evaluated by 4 analysts over the past three months, with a shift towards a more bearish stance. The average 12-month price target has been lowered by 12.38% to $23.00, with a high estimate of $24.00 and a low of $21.00. Analysts from JP Morgan, Citigroup, BMO Capital, and RBC Capital have all lowered their price targets. DXC Technology's financial performance shows a decline in revenue growth, below-average net margin and ROE, and a high debt-to-equity ratio, indicating potential financial challenges.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 6:00 pm

MMM

Five analysts have recently updated their ratings on 3M (NYSE:MMM), with four maintaining an indifferent stance and one rating it as somewhat bearish. The average 12-month price target is now $103.2, up from $102.60, with individual analysts adjusting their targets both upwards and downwards. 3M's financials show a revenue decline of -3.56%, a high net margin of -24.96%, an ROE of -33.28%, an ROA of -4.21%, and a debt-to-equity ratio of 3.6, indicating mixed financial health and potential risks.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 6:00 pm

MGNX

Macrogenics (NASDAQ:MGNX) received mixed reviews from 5 analysts, with recent ratings ranging from bullish to somewhat bullish. The average 12-month price target is $14.00, a significant increase from the previous $10.33. Analysts from JMP Securities, Citigroup, Stifel, HC Wainwright & Co., and Guggenheim have adjusted their price targets and ratings, reflecting changes in market dynamics and company performance. Macrogenics, a biotech company specializing in antibody-based cancer therapeutics, has a market cap below industry benchmarks and experienced a significant revenue decline of -75.09% over the last quarter. However, it has a high net margin of 168.84%, an ROE of 9.6%, and an ROA of 5.44%, indicating strong profitability and financial management.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 6:00 pm

FCX

Freeport-McMoRan Inc (NYSE:FCX) reported Q4 fiscal 2023 revenue of $5.91 billion, surpassing estimates of $5.86 billion. Adjusted EPS was $0.27, above the consensus of $0.22. Copper sales increased by 7.1% Y/Y, and gold sales by 19.9% Y/Y. The company achieved a 90% completion milestone on Indonesia smelter projects, saw a 12.6% Y/Y increase in operating income, and ended the quarter with $4.76 billion in cash. FCX expects strong sales volumes and operating cash flows for 2024. Shares rose 5.2% to $40.16.

Portfolio Pulse from Akanksha Bakshi

January 24, 2024 | 5:05 pm

MOS

Four analysts have recently updated their ratings on Mosaic (NYSE:MOS), showing a mix of indifference and slight bullishness. The average 12-month price target is now $36.25, down 6.26% from previous estimates, with a high of $42.00 and a low of $34.00. Analysts from Mizuho, Wells Fargo, Barclays, and RBC Capital have adjusted their price targets and ratings, reflecting a nuanced view of Mosaic's market position. Mosaic, a major phosphate and potash producer, has seen a -33.66% decline in revenue growth and faces profitability challenges with a net margin of -0.12% and ROE of -0.03%. Despite this, Mosaic maintains a healthy debt-to-equity ratio of 0.32.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 5:00 pm

CSIQ

Analyst ratings for Canadian Solar (NASDAQ:CSIQ) show mixed sentiments with a decrease in the average 12-month price target from $43.00 to $32.40. Brian Lee of Goldman Sachs raised the target from $25.00 to $28.00, maintaining a 'Neutral' rating. Jon Windham of UBS and Colin Rusch of Oppenheimer lowered their targets, with 'Buy' and 'Outperform' ratings, respectively. Mark Strouse of JP Morgan also lowered his target, assigning an 'Underweight' rating. Canadian Solar's financial health shows a negative revenue trend, a high net margin, and challenges in debt management.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 5:00 pm

PRPL

Purple Innovation's stock is up following the announcement of an improved balance sheet, providing more financial flexibility for growth. The company also confirmed its 2023 guidance remains unchanged.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 4:46 pm

TXT

Textron Inc (NYSE:TXT) shares surged after Q4 results showed a mixed performance with sales missing estimates but adjusted EPS beating expectations. Textron Aviation's revenues declined, while Bell and Industrial segments reported revenue growth. The company announced a restructuring plan expected to save $75 million annually. Textron also provided a positive FY24 outlook with higher revenue and EPS projections than consensus estimates, and shared plans for continued investments in new products and programs. Shares rose 7.97% to $85.65.

Portfolio Pulse from Lekha Gupta

January 24, 2024 | 4:32 pm

ELV

Elevance Health Inc (NYSE:ELV) reported Q4 2023 revenues of $42.45 billion, a 7% increase Y/Y, surpassing consensus estimates. Adjusted EPS was $5.62, slightly missing the $5.64 consensus. Profit declined 1% Y/Y to $856 million. Membership dropped by 570,000, with Medicaid enrollment down by over 1 million. The company increased its quarterly dividend by 10.1% to $1.63 per share and provided a 2024 outlook with flat-to-low-single digit revenue growth and adjusted EPS of over $37.10. ELV shares rose 2.53% to $484.13.

Portfolio Pulse from Vandana Singh

January 24, 2024 | 4:15 pm